{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:32:19Z","timestamp":1784082739995,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,1,22]],"date-time":"2011-01-22T00:00:00Z","timestamp":1295654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00108-010-2791-2","type":"journal-article","created":{"date-parts":[[2011,1,20]],"date-time":"2011-01-20T13:08:38Z","timestamp":1295528918000},"page":"283-296","source":"Crossref","is-referenced-by-count":4,"title":["Chronische myeloische Leuk\u00e4mie","Chronic myeloid leukemia"],"prefix":"10.1007","volume":"52","author":[{"given":"A.","family":"Burchert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,22]]},"reference":[{"key":"2791_CR1","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041\u20136051","journal-title":"J Clin Oncol"},{"key":"2791_CR2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809\u20131820","journal-title":"Blood"},{"key":"2791_CR3","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","volume":"98","author":"Bonifazi","year":"2001","unstructured":"Bonifazi F, Vivo A de, Rosti G et al (2001) Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98:3074\u20133081","journal-title":"Blood"},{"key":"2791_CR4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","volume":"28","author":"Burchert","year":"2010","unstructured":"Burchert A, Muller MC, Kostrewa P et al (2010) Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 28:1429\u20131435","journal-title":"J Clin Oncol"},{"key":"2791_CR5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/10428190400012029","volume":"46","author":"Burchert","year":"2005","unstructured":"Burchert A, Neubauer A (2005) Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma 46:167\u2013175","journal-title":"Leuk Lymphoma"},{"key":"2791_CR6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","volume":"101","author":"Burchert","year":"2003","unstructured":"Burchert A, Wolfl S, Schmidt M et al (2003) Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101:259\u2013264","journal-title":"Blood"},{"key":"2791_CR7","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","volume":"22","author":"Cortes","year":"2008","unstructured":"Cortes J, Kim DW, Raffoux E et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22:2176\u20132183","journal-title":"Leukemia"},{"key":"2791_CR8","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"2791_CR9","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/cncr.22535","volume":"109","author":"Fruehauf","year":"2007","unstructured":"Fruehauf S, Topaly J, Buss EC et al (2007) Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 109:1543\u20131549","journal-title":"Cancer"},{"key":"2791_CR10","first-page":"46","volume":"93","author":"Giles","year":"2008","unstructured":"Giles J, Larson RA, Kantarjian HM et al (2008) Nilotinib in chronic myelogenous leukaemia in blast crises (CML-BC) patients with imatinib-resistance or -intolerance: updated phase 2 results. Haematologica 93:46 abstract 0117","journal-title":"Haematologica"},{"key":"2791_CR11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E et al (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319\u2013325","journal-title":"Blood"},{"key":"2791_CR12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM et al (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia working party of the European Group for blood and marrow transplantation. Lancet 352:1087\u20131092","journal-title":"Lancet"},{"key":"2791_CR13","first-page":"509","volume":"12","author":"Gratwohl","year":"1993","unstructured":"Gratwohl A, Hermans J, Niederwieser D et al (1993) Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia working party of the European Group for bone marrow transplantation. Bone Marrow Transplant 12:509\u2013516","journal-title":"Bone Marrow Transplant"},{"key":"2791_CR14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850\u2013858","journal-title":"J Natl Cancer Inst"},{"key":"2791_CR15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M (2007) Chronic myeloid leukaemia. Lancet 370:342\u2013350","journal-title":"Lancet"},{"key":"2791_CR16","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200\u20131206","journal-title":"Leukemia"},{"key":"2791_CR17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061","journal-title":"Leukemia"},{"key":"2791_CR18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28\u201337","journal-title":"Blood"},{"key":"2791_CR19","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"Hughes","year":"2009","unstructured":"Hughes T, Saglio G, Branford S et al (2009) Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 27:4204\u20134210","journal-title":"J Clin Oncol"},{"key":"2791_CR20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D et al (2006) Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20:1767\u20131773","journal-title":"Leukemia"},{"key":"2791_CR21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","volume":"112","author":"Jabbour","year":"2008","unstructured":"Jabbour E, Kantarjian H, Jones D et al (2008) Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112:53\u201355","journal-title":"Blood"},{"key":"2791_CR22","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","volume":"113","author":"Kantarjian","year":"2009","unstructured":"Kantarjian H, Cortes J, Kim DW et a (2009) Phase 3 study of dasatinib 140\u00a0mg once daily versus 70\u00a0mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113:6322\u20136329","journal-title":"Blood"},{"key":"2791_CR23","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","volume":"115","author":"Kantarjian","year":"2009","unstructured":"Kantarjian H, Pasquini R, Levy V et al (2009) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 115:4136\u20134147","journal-title":"Cancer"},{"key":"2791_CR24","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270","journal-title":"N Engl J Med"},{"key":"2791_CR25","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","volume":"99","author":"Kantarjian","year":"2002","unstructured":"Kantarjian HM, Cortes J, O\u2019Brien S et al (2002) Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99:3547\u20133553","journal-title":"Blood"},{"key":"2791_CR26","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540\u20133546","journal-title":"Blood"},{"key":"2791_CR27","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","volume":"26","author":"Khorashad","year":"2008","unstructured":"Khorashad JS, Lavallade H de, Apperley JF et al (2008) Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26:4806\u20134813","journal-title":"J Clin Oncol"},{"key":"2791_CR28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.20.1.214","volume":"20","author":"Mahon","year":"2002","unstructured":"Mahon FX, Delbrel X, Cony-Makhoul P et al (2002) Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20:214\u2013220","journal-title":"J Clin Oncol"},{"key":"2791_CR29","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J et al; Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"2791_CR30","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381\u20132388","journal-title":"J Clin Oncol"},{"key":"2791_CR31","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C et al (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018\u20131023","journal-title":"Nat Med"},{"key":"2791_CR32","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","volume":"114","author":"Muller","year":"2009","unstructured":"Muller MC, Cortes JE, Kim DW et al (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114:4944\u20134953","journal-title":"Blood"},{"key":"2791_CR33","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"Noens","year":"2009","unstructured":"Noens L, Lierde MA van, De Bock R et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401\u20135411","journal-title":"Blood"},{"key":"2791_CR34","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"O","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500\u20134505","journal-title":"Cancer Res"},{"key":"2791_CR35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.13529","volume":"94","author":"Palandri","year":"2009","unstructured":"Palandri F, Castagnetti F, Alimena G et al (2009) The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600\u00a0mg: the GIMEMA CML working party experience after a 7-year follow-up. Haematologica 94:205\u2013212","journal-title":"Haematologica"},{"key":"2791_CR36","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","volume":"93","author":"Palandri","year":"2008","unstructured":"Palandri F, Castagnetti F, Testoni N et al (2008) Chronic myeloid leukemia in blast crisis treated with imatinib 600\u00a0mg: outcome of the patients alive after a 6-year follow-up. Haematologica 93:1792\u20131796","journal-title":"Haematologica"},{"key":"2791_CR37","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619\u20131630","journal-title":"Blood"},{"key":"2791_CR38","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259","journal-title":"N Engl J Med"},{"key":"2791_CR39","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"Saussele","year":"2010","unstructured":"Saussele S, Lauseker M, Gratwohl A et al (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115:1880\u20131885","journal-title":"Blood"},{"key":"2791_CR40","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW et al (2008) Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204\u20133212","journal-title":"J Clin Oncol"},{"key":"2791_CR41","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M et al (1984) Prognostic discrimination in \u201egood-risk\u201c chronic granulocytic leukemia. Blood 63:789\u2013799","journal-title":"Blood"},{"key":"2791_CR42","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","volume":"104","author":"Thomas","year":"2004","unstructured":"Thomas DA, O\u2019Brien S, Cortes J et al (2004) Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104:1624\u20131630","journal-title":"Blood"},{"key":"2791_CR43","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I et al (2006) High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24:460\u2013466","journal-title":"J Clin Oncol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-010-2791-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-010-2791-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-010-2791-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T21:03:54Z","timestamp":1592255034000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-010-2791-2"}},"subtitle":["Diagnostik, Therapie und Zukunftsstrategie","Diagnostics, therapy and future strategy"],"short-title":[],"issued":{"date-parts":[[2011,1,22]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["2791"],"URL":"https:\/\/doi.org\/10.1007\/s00108-010-2791-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,22]]}}}